156 380

Cited 13 times in

Lafutidine versus lansoprazole in combination with clarithromycin and amoxicillin for one versus two weeks for Helicobacter pylori eradication in Korea.

Authors
Kim, N; Park, SH; Seo, GS; Lee, SW; Kim, JW; Lee, KJ; Shin, WC; Kim, TN; Park, MI; Park, JJ; Hong, SJ; Shim, KN; Kim, SW; Shin, YW; Chang, YW; Chun, HJ; Lee, OJ; Jeon, WJ; Park, CG; Cho, CM; Park, CH; Won, SY; Lee, GH; Park, KS; Shin, JE; Kim, HU; Park, JY; Chae, HS; Song, GA; Kim, JG; Yoon, BC; Seol, S; Jung, HC; Chung, IS
Citation
Helicobacter, 13(6):542-549, 2008
Journal Title
Helicobacter
ISSN
1083-43891523-5378
Abstract
BACKGROUND AND AIMS: Lafutidine is a novel H(2)-receptor antagonist with gastroprotective activity that includes enhancement of gastric mucosal blood flow. The aim of the present study was to test the efficacy of 7- or 14-day lafutidine-clarithromycin-amoxicillin therapy versus a lansoprazole-based regimen for Helicobacter pylori eradication. METHODS: Four hundred and sixty-three patients with H. pylori-infected peptic ulcer disease were randomized to one of four regimens: (1) lafutidine (20 mg b.i.d.), clarithromycin (500 mg b.i.d.) and amoxicillin (1000 mg b.i.d.) for 7 days (the 7LFT group) or (2) for 14 days (the 14LFT group); (3) lansoprazole (30 mg b.i.d.), clarithromycin (500 mg b.i.d.), and amoxicillin (1000 mg b.i.d.) for 7 days (the 7LPZ group); or (4) for 14 days (the 14LPZ group). The eradication rates, drug compliance, and adverse effects among the four regimens were compared. RESULTS: The eradication rates by the intention-to-treat and per-protocol analyses in the 7LFT and 7LPZ groups were 76.5% and 81.6%, and 76.9% and 82.0% (p = .94 and .95), respectively. The eradication rates by intention-to-treat and per-protocol analyses in the 14LFT and 14LPZ groups were 78.2% and 82.2%, and 80.4% and 85.9% (p = .70 and .49), respectively. The treatment duration for 7 days or 14 days did not affect the eradication rates. In addition, the adverse effect rates and discontinuation rates were similar among the four groups. Furthermore, the ulcer cure rate and symptom response rate were similar in the lafutidine and lansoprazole groups. CONCLUSION: The results of this study showed that lafutidine-clarithromycin-amoxicillin therapy was a safe and effective as lansoprazole-based triple therapy for the eradication rate of H. pylori, and could be considered as an additional treatment option.
MeSH terms
2-Pyridinylmethylsulfinylbenzimidazoles/administration & dosage2-Pyridinylmethylsulfinylbenzimidazoles/adverse effects2-Pyridinylmethylsulfinylbenzimidazoles/therapeutic use*Acetamides/administration & dosageAcetamides/adverse effectsAcetamides/therapeutic use*AdultAgedAmoxicillin/administration & dosageAmoxicillin/adverse effectsAmoxicillin/therapeutic use*Anti-Bacterial Agents/administration & dosageAnti-Bacterial Agents/adverse effectsAnti-Bacterial Agents/therapeutic use*Anti-Ulcer Agents/administration & dosageAnti-Ulcer Agents/adverse effectsAnti-Ulcer Agents/therapeutic use*Clarithromycin/administration & dosageClarithromycin/adverse effectsClarithromycin/therapeutic use*FemaleHelicobacter Infections/drug therapy*Helicobacter pylori/drug effects*HumansKoreaMaleMiddle AgedPiperidines/administration & dosagePiperidines/adverse effectsPiperidines/therapeutic use*Pyridines/administration & dosagePyridines/adverse effectsPyridines/therapeutic use*Time FactorsTreatment Outcome
DOI
10.1111/j.1523-5378.2008.00648.x
PMID
19166420
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Gastroenterology
AJOU Authors
이광재
Full Text Link
Files in This Item:
Full-Text Not Available.txtDownload
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse